Impact of Safety Warnings on Drug Utilization: Marketplace Life Span of Cisapride and Troglitazone

Study Objective. To evaluate the impact of safety alerts on the volume of cisapride and troglitazone usage. Design. Retrospective database analysis. Setting. University research center. Material. Idaho Medicaid claims data from January 1994–July 2000. Measurements and Main Results. Monthly counts of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmacotherapy 2004-08, Vol.24 (8), p.978-986
Hauptverfasser:	Wilkinson, Julie J., Force, Rex W., Cady, Paul S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Chromans - adverse effects cisapride Cisapride - adverse effects Databases, Factual Drug Labeling drug utilization Gastrointestinal Agents - adverse effects Humans Hypoglycemic Agents - adverse effects Pharmacoepidemiology Product Surveillance, Postmarketing - methods Retrospective Studies safety warnings Thiazolidinediones - adverse effects troglitazone United States United States Food and Drug Administration
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Study Objective. To evaluate the impact of safety alerts on the volume of cisapride and troglitazone usage. Design. Retrospective database analysis. Setting. University research center. Material. Idaho Medicaid claims data from January 1994–July 2000. Measurements and Main Results. Monthly counts of total and new prescriptions filled for cisapride and troglitazone were analyzed graphically over time as a function of all prescriptions. New prescriptions were defined as those filled by patients who had not received the drug within the previous year. A binomial comparison of the 5 months before and after each safety alert was conducted by Poisson distribution. Overall and new cisapride usage increased after the first alert, which occurred in February 1995 (p
ISSN:	0277-0008 1875-9114
DOI:	10.1592/phco.24.11.978.36136